QUIDELORTHO CORP Reports 8.4% Increase in Revenue for Quarter Ended June 30 2023
August 11, 2023
☀️Earnings Overview
For the quarter ended June 30 2023, QUIDELORTHO CORP ($NASDAQ:QDEL) saw total revenue of USD 665.1 million, a rise of 8.4% from the same period in the previous year. However, net income for the quarter decreased to USD -53.2 million, compared to the figure of USD 19.3 million reported in the corresponding period of the prior year.
Analysis
GoodWhale has conducted an in-depth analysis of QUIDELORTHO CORP‘s wellbeing. The results of the analysis show that QUIDELORTHO CORP is an investment with a high risk rating. This implies that the financial and business aspects of this company should be carefully assessed and considered before investing. GoodWhale has detected two risk warnings in the income sheet and balance sheet which are important factors to consider in the assessment process. If you are interested in learning more about these risk warnings, please register with us so that we can provide you with further information. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Quidelortho Corp. More…
| Total Revenues | Net Income | Net Margin |
| 3.16k | 45.1 | 3.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Quidelortho Corp. More…
| Operations | Investing | Financing |
| 318 | -200.3 | -317 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 8.55k | 3.55k | 74.89 |
Key Ratios Snapshot
Some of the financial key ratios for Quidelortho Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 69.0% | 17.1% | 7.0% |
| FCF Margin | ROE | ROA |
| 3.4% | 2.7% | 1.6% |
Peers
Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.
However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.
– LifePoint Inc ($OTCPK:LFPI)
LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.
– Bloom Health Partners Inc ($OTCPK:BLMHF)
The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.
– Talis Biomedical Corp ($NASDAQ:TLIS)
Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.
Summary
Investors should perform a cautious analysis of Quidelortho Corp‘s financial results for the quarter ended June 30 2023. Total revenue increased 8.4%, to USD 665.1 million, while net income decreased significantly from the previous year, to USD -53.2 million. Investors should consider the company’s overall financial performance when making an investment decision. They may also want to factor in future expectations for the company.
Related Posts
Recent Posts
